Johnson & Johnson [NYSE: JNJ] closed the trading session at $146.82. The stocks have a year to date performance of -6.33 percent and weekly performance of -1.54 percent. The stock has been moved at -1.46 percent over the last six months. The stock has performed
Johnson & Johnson [NYSE: JNJ] jumped around 1.21 points on Monday, while shares priced at $149.12 at the close of the session, up 0.82%. Compared to the average trading volume of 7.49M shares, JNJ reached a trading volume of 9510066 in the most recent trading
Johnson & Johnson [NYSE: JNJ] jumped around 0.07 points on Monday, while shares priced at $147.59 at the close of the session, up 0.05%. Compared to the average trading volume of 7.19M shares, JNJ reached a trading volume of 8490880 in the most recent trading
Johnson & Johnson [NYSE: JNJ] loss -0.52% or -0.8 points to close at $151.59 with a heavy trading volume of 5933673 shares. The company report on April 5, 2024 at 11:21 PM that CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S.
Johnson & Johnson [NYSE: JNJ] price plunged by -0.03 percent to reach at -$0.05. The company report on March 12, 2024 at 9:15 AM that Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge. ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership
Johnson & Johnson [NYSE: JNJ] gained 0.35% on the last trading session, reaching $155.77 price per share at the time. If compared to the average trading volume of 6.99M shares, JNJ reached a trading volume of 6863112 in the most recent trading day, which is
Johnson & Johnson [NYSE: JNJ] stock went on a downward path that fall over -0.90% on Monday, amounting to a one-week price decrease of less than -2.77%. The company report on March 12, 2024 at 9:15 AM that Artelo Biosciences Selected as a Finalist in
Johnson & Johnson [NYSE: JNJ] traded at a high on Tuesday, posting a 0.94 gain after which it closed the day’ session at $162.74. The company report on March 12, 2024 at 9:15 AM that Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s
Johnson & Johnson [NYSE: JNJ] plunged by -$2.28 during the normal trading session on while it closed the day at $159.84. The company report on March 1, 2024 at 3:59 PM that RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for
Johnson & Johnson [NYSE: JNJ] surged by $0.19 during the normal trading session on while it closed the day at $160.98. The company report on February 20, 2024 at 4:25 PM that TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of
© 2024, Powered by Smart TechOne
